Newswise Curated News Channel: NEJM

Study Finds Transfusing More Blood Reduces Risk of Death at Six Months in Heart-Attack Patients With Anemia

Rutgers University-New Brunswick — Mon, 23 Dec 2024 18:05:24 EST

A study led by Rutgers professor finds more liberal blood transfusions have more favorable results

Research Shows New Treatment Could Delay Cancer Progression in Patients with High-Risk Smoldering Multiple Myeloma

Mayo Clinic — Tue, 10 Dec 2024 14:05:51 EST

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.

New Research from Children's Hospital of Philadelphia to Transform Standard of Care Across the Globe for Newly Diagnosed Children with B-cell Acute Lymphoblastic Leukemia

Children's Hospital of Philadelphia — Sat, 07 Dec 2024 10:00:32 EST

Researchers at Children's Hospital of Philadelphia (CHOP) and the Children's Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.

Novel CAR TCell Therapy Obe-Cel Demonstrates High Response Rates in Adult Patients with Advanced B-Cell ALL

University of Texas MD Anderson Cancer Center — Wed, 27 Nov 2024 17:05:51 EST

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

Twice-Yearly Lenacapavir for PrEP Reduces HIV Infections by 96%

Yale School of Medicine — Wed, 27 Nov 2024 17:00:02 EST

Study Reveals Targeted Procedure to Prevent Recurrent Brain Bleeds

UC San Diego Health — Thu, 21 Nov 2024 17:00:48 EST

Embargoed Hodgkin's Lymphoma NEJM Study: Live event with URMC

Newswise — Thu, 21 Nov 2024 13:00:03 EST

Embargoed Hodgkin's Lymphoma NEJM Study: Live event with URMC - Live Event. 10/14/2024

Changing the Definition of Cerebral Palsy

Michigan Medicine - University of Michigan — Tue, 19 Nov 2024 15:50:25 EST

In the United States, there are currently more adults living with cerebral palsy than children. Despite this, the Centers for Disease Control and Prevention still label cerebral palsy as "the most common motor disability in childhood."

Yale Study Reveals Significant Weight Loss and Reduced Diabetes Risk with Tirzepatide

Yale School of Medicine — Mon, 18 Nov 2024 12:15:55 EST

Children's Hospital of Philadelphia Researchers Announce Promising Results from First-of-its-Kind, Multicenter, Phase 1 Gene Therapy Trial for Danon Disease

Children's Hospital of Philadelphia — Mon, 18 Nov 2024 11:55:51 EST

Researchers at Children's Hospital of Philadelphia (CHOP) announced encouraging results from the first ever gene therapy trial for Danon disease (DD), a rare, X-linked heart condition caused by a single gene mutation. The phase 1 trial was a collaboration between CHOP and the University of California, San Diego Medical Center, the University of Colorado, Anschutz Medical Center, Boston Children's Hospital and Rocket Pharmaceuticals. The data on the results of the RP-A501 Phase 1 trial, presented at a late breaking session today at the American Heart Association Scientific Sessions 2024 in Chicago, were also published in the New England Journal of Medicine.

Treatment Advances, Predictive Biomarkers Stand to Improve Bladder Cancer Care

University of North Carolina Health Care System — Wed, 13 Nov 2024 17:00:00 EST

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a New England Journal of Medicine editorial published by Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center.

Study Finds Early TAVR Can Be Beneficial for Patients with Asymptomatic Severe Aortic Stenosis

Cardiovascular Research Foundation (CRF) — Tue, 29 Oct 2024 11:35:18 EST

The first powered randomized trial examining early intervention with transcatheter aortic valve replacement (TAVR) in patients with asymptomatic, severe aortic stenosis (AS) found this strategy to be both a safe and effective alternative to clinical surveillance (CS). Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Results were also published simultaneously in the New England Journal of Medicine.

New Treatment for Cancer-Related Wasting Disease

Cedars-Sinai — Mon, 28 Oct 2024 10:35:03 EST

A syndrome called cachexia, which triggers unexplained loss of weight and muscle mass, causes severe illness and death among patients with cancer and other serious health conditions.

Critical Steps and More Research Needed to Support Physicians' Mental Health, Experts Say

Michigan Medicine - University of Michigan — Wed, 23 Oct 2024 17:05:43 EST

A review of what's known about the crisis in physician well-being, and what can be done to address it, also suggests a need for action by health systems, and more research.

Study: AI Could Transform How Hospitals Produce Quality Reports

UC San Diego Health — Mon, 21 Oct 2024 11:35:46 EST

University of California San Diego School of Medicine researchers find advanced AI could lead to easier, faster and more efficient hospital quality reporting.

Breakthrough Clinical Trial Reveals Better Treatment for Advanced Classic Hodgkin Lymphoma

Roswell Park Comprehensive Cancer Center — Wed, 16 Oct 2024 20:45:30 EST

Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated. Details appear in a study published today in The New England Journal of Medicine. Drs. Kara Kelly of Roswell Park Comprehensive Cancer Center and Sharon Castellino of Children's Healthcare of Atlanta and Emory University School of Medicine/Winship Cancer Institute of Emory University served as pediatric leads of this important trial in children and adults with lymphoma.

Study Finds HIV-To-HIV Kidney Transplants Are as Safe and Effective as Those Using Organs From Donors Without HIV

Johns Hopkins Medicine — Wed, 16 Oct 2024 17:15:29 EST

According to findings from a multicenter study led by Johns Hopkins Medicine and released today in The New England Journal of Medicine (NEJM), transplanting kidneys from deceased donors who had the human immunodeficiency virus (HIV) to recipients with HIV is safe. Perhaps more importantly, the study authors also found that HIV-to-HIV kidney transplants are comparable in effectiveness to those using organs from donors without HIV.

In Landmark Study, Immunotherapy Boosts Survival of Advanced Hodgkin Lymphoma

University of Rochester Medical Center — Wed, 16 Oct 2024 17:00:00 EST

A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the disease. The New England Journal of Medicine published the innovative clinical trial results this week.

Cycling for Critically Ill Patients Improves Physical Function, Reduces Hospital Stays: Systematic Review

McMaster University — Thu, 10 Oct 2024 09:05:15 EST

A new systematic review led by researchers in Hamilton, Canada has shown that specialized in-bed cycling therapy, when used in the intensive care unit with critically ill patients, leads to better physical function and a one-day shorter length of stay in the ICU.

NEJM: Results From Targeted Therapy for Ulcerative Colitis Study

Cedars-Sinai — Wed, 25 Sep 2024 19:05:40 EST

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission.